S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
A 'soft landing' or a recession? How each one might affect America's households and businesses
New CBOE “special perk” helps traders target income every weekend (Ad)
How major US stock indexes fared Friday, 12/8/2023
MarketBeat Week in Review – 12/4 - 12/8
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
FTC opens inquiry of Chevron-Hess merger, marking second review this week of major oil industry deal
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Indiana secretary of state appeals ruling for US Senate candidate seeking GOP nod
What is carbon capture and why does it keep coming up at COP28?
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
A 'soft landing' or a recession? How each one might affect America's households and businesses
New CBOE “special perk” helps traders target income every weekend (Ad)
How major US stock indexes fared Friday, 12/8/2023
MarketBeat Week in Review – 12/4 - 12/8
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
FTC opens inquiry of Chevron-Hess merger, marking second review this week of major oil industry deal
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Indiana secretary of state appeals ruling for US Senate candidate seeking GOP nod
What is carbon capture and why does it keep coming up at COP28?
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
A 'soft landing' or a recession? How each one might affect America's households and businesses
New CBOE “special perk” helps traders target income every weekend (Ad)
How major US stock indexes fared Friday, 12/8/2023
MarketBeat Week in Review – 12/4 - 12/8
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
FTC opens inquiry of Chevron-Hess merger, marking second review this week of major oil industry deal
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Indiana secretary of state appeals ruling for US Senate candidate seeking GOP nod
What is carbon capture and why does it keep coming up at COP28?
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
A 'soft landing' or a recession? How each one might affect America's households and businesses
New CBOE “special perk” helps traders target income every weekend (Ad)
How major US stock indexes fared Friday, 12/8/2023
MarketBeat Week in Review – 12/4 - 12/8
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
FTC opens inquiry of Chevron-Hess merger, marking second review this week of major oil industry deal
Amazon asks federal judge to dismiss the FTC's antitrust lawsuit against the company
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Indiana secretary of state appeals ruling for US Senate candidate seeking GOP nod
What is carbon capture and why does it keep coming up at COP28?

Repligen Stock Price, News & Analysis (NASDAQ:RGEN)

$159.27
-2.60 (-1.61%)
(As of 12/8/2023 ET)
Compare
Today's Range
$158.33
$164.71
50-Day Range
$114.17
$164.94
52-Week Range
$110.45
$200.98
Volume
472,497 shs
Average Volume
541,630 shs
Market Capitalization
$8.89 billion
P/E Ratio
78.46
Dividend Yield
N/A
Price Target
$189.55

Repligen MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.82 Rating Score
Upside/​Downside
19.0% Upside
$189.55 Price Target
Short Interest
Bearish
11.54% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.33
Upright™ Environmental Score
News Sentiment
0.71mentions of Repligen in the last 14 days
Based on 15 Articles This Week
Insider Trading
Selling Shares
$557,328 Sold Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.44 out of 5 stars

Medical Sector

156th out of 942 stocks

Biological Products, Except Diagnostic Industry

24th out of 161 stocks


RGEN stock logo

About Repligen Stock (NASDAQ:RGEN)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

RGEN Stock Price History

RGEN Stock News Headlines

All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Benchmark Downgrades Repligen (NASDAQ:RGEN) to Hold
Benchmark Downgrades Repligen (RGEN)
Repligen downgraded to Hold from Buy at Benchmark
The Latest Analyst Ratings for Repligen
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
Repligen (RGEN) Earnings Dates & Reports
Does Repligen Corp. (RGEN) Have a Bright Future?
Analyst Expectations for Repligen's Future
RBC Capital Reaffirms Their Buy Rating on Repligen (RGEN)
Repligen (RGEN) Shares Rise on Q3 Earnings & Revenue Beat
Q3 2023 Repligen Corp Earnings Call
Repligen: Q3 Earnings Snapshot
A Preview Of Repligen's Earnings
See More Headlines
Receive RGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Repligen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/31/2023
Today
12/09/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/28/2024

Industry, Sector and Symbol

Industry
Medical Instruments & Supplies
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:RGEN
CUSIP
75991610
Employees
2,025
Year Founded
1981

Price Target and Rating

Average Stock Price Target
$189.55
High Stock Price Target
$210.00
Low Stock Price Target
$165.00
Potential Upside/Downside
+19.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.82
Research Coverage
11 Analysts

Profitability

Net Income
$185.96 million
Pretax Margin
18.79%

Debt

Sales & Book Value

Annual Sales
$669.78 million
Cash Flow
$4.20 per share
Book Value
$34.41 per share

Miscellaneous

Free Float
55,218,000
Market Cap
$8.89 billion
Optionable
Optionable
Beta
1.08

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report














RGEN Stock Analysis - Frequently Asked Questions

Should I buy or sell Repligen stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Repligen in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RGEN shares.
View RGEN analyst ratings
or view top-rated stocks.

What is Repligen's stock price target for 2024?

11 equities research analysts have issued 1 year target prices for Repligen's shares. Their RGEN share price targets range from $165.00 to $210.00. On average, they anticipate the company's stock price to reach $189.55 in the next year. This suggests a possible upside of 19.0% from the stock's current price.
View analysts price targets for RGEN
or view top-rated stocks among Wall Street analysts.

How have RGEN shares performed in 2023?

Repligen's stock was trading at $169.31 at the start of the year. Since then, RGEN stock has decreased by 5.9% and is now trading at $159.27.
View the best growth stocks for 2023 here
.

When is Repligen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024.
View our RGEN earnings forecast
.

How were Repligen's earnings last quarter?

Repligen Co. (NASDAQ:RGEN) announced its quarterly earnings data on Tuesday, October, 31st. The biotechnology company reported $0.23 EPS for the quarter, topping the consensus estimate of $0.14 by $0.09. The biotechnology company earned $141.20 million during the quarter, compared to analysts' expectations of $140.68 million. Repligen had a net margin of 17.29% and a trailing twelve-month return on equity of 6.08%. Repligen's revenue for the quarter was down 29.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.77 earnings per share.

What guidance has Repligen issued on next quarter's earnings?

Repligen issued an update on its FY23 earnings guidance on Tuesday, October, 31st. The company provided EPS guidance of $1.70-1.76 for the period, compared to the consensus earnings per share estimate of $1.74. The company issued revenue guidance of $635-645 million, compared to the consensus revenue estimate of $644.49 million.

What is Tony J. Hunt's approval rating as Repligen's CEO?

13 employees have rated Repligen Chief Executive Officer Tony J. Hunt on Glassdoor.com. Tony J. Hunt has an approval rating of 52% among the company's employees. This puts Tony J. Hunt in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Repligen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Repligen investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Block (SQ), Advanced Micro Devices (AMD), DocuSign (DOCU), Walt Disney (DIS), Netflix (NFLX), Tesla (TSLA) and ServiceNow (NOW).

Who are Repligen's major shareholders?

Repligen's stock is owned by many different retail and institutional investors. Top institutional shareholders include Sands Capital Management LLC (2.81%), Artisan Partners Limited Partnership (2.79%), Wellington Management Group LLP (2.50%), Bank of New York Mellon Corp (2.14%), Ameriprise Financial Inc. (2.07%) and Impax Asset Management Group plc (1.74%). Insiders that own company stock include Anthony Hunt, Christine Gebski, James Bylund, Jon Snodgres, Karen A Dawes, Karen A Dawes, Manner Carrie Eglinton, Martin D Madaus, Nicolas Barthelemy, Ralf Kuriyel and Thomas F Ryan Jr.
View institutional ownership trends
.

How do I buy shares of Repligen?

Shares of RGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does Repligen have any subsidiaries?
The following companies are subsidiares of Repligen: ARTeSYN Biosolutions Holdings Ireland Limite, C Technologies Inc., Engineered Molding Technology LLC, Non-Metallic Solutions Inc, Repligen (Shanghai) Biotechnology Co. Ltd., Repligen Europe B.V., Repligen GmbH, Repligen India Private Limited, Repligen Japan LLC, Repligen Korea Co. Ltd., Repligen Singapore Pte. Ltd., Repligen Sweden AB, and Spectrum Lifesciences LLC.
Read More
This page (NASDAQ:RGEN) was last updated on 12/9/2023 by MarketBeat.com Staff

My Account -